The recalled 100 mg/25 mg losartan and potassium/hydrochlorothiazide tablets contained small amounts of N-nitrosodiethylamine, or NDEA, according to a company recall notice shared on the Food and ...

Ascendis Pharma A/S announced that its Board of Directors approved a plan to allocate approximately $25 million in the first quarter of 2025 for a share repurchase program and the net settlement ...

COPENHAGEN - Ascendis Pharma A/S (NASDAQ: ASND), a biopharmaceutical company valued at $7.15 billion, has initiated a share repurchase program, with plans to buy back up to $18.25 million of its ...

Novo Nordisk and Ascendis Pharma have partnered to develop therapies for metabolic and cardiovascular diseases, including a once-monthly GLP-1 receptor agonist that will initially target type 2 ...

So Ascendis' drug appears to be as effective as BioMarin ... So it accounted for approximately 25% of total revenues ($712 million). In this context, BioMarin's stock dropping ~17% on Monday ...

BioMarin serves that need with its CNP analog Voxzogo—the centerpiece of its growth strategy—but that drug needs to be injected once a day. Ascendis’ TransCon CNP could challenge Voxzogo.

Children treated with the Ascendis drug grew an average of 1.49 centimeters in a year relative to a placebo, achieving the primary goal of the study. BioMarin Pharmaceutical was trading lower in ...

In prisons and jails across the country, a bulky tablet enclosed in a screwed-on plastic case has become the hottest new device. Featuring limited online access, the tablets allow incarcerated ...

London: Ascendis Pharma said on Monday the U.S. Food & Drug Administration had approved its therapy to treat adult patients with a hormone disorder, sending the Danish drugmaker's shares more than ...

After all, the company was initially set to bring the drug to the market 15 months ago before the FDA rejected it with a surprise complete response letter (CRL). Then three months ago, Ascendis ...